Abiraterone and Zytiga are vital drugs in the treatment of prostate cancer. This article compares their uses, benefits, and key differences to help patients and healthcare providers make informed decisions.
Abiraterone vs. Zytiga
Abiraterone acetate is the active ingredient in both medications, with Zytiga being the brand name. Both inhibit CYP17, reducing androgen levels to manage prostate cancer.
Uses and Indications
Abiraterone: Used in combination with prednisone for mCRPC.
Zytiga: Also used for mCRPC, often preferred for its proven efficacy and brand recognition.
Dosage and Administration
Both medications are typically taken at a dosage of 500 mg daily, combined with prednisone. The formulation (tablet strength and number of tablets) may vary.
Side Effects
Common side effects include hypertension, hypokalemia, and liver function issues. Both medications require regular monitoring and supportive care to manage these effects.
Pricing and Availability
Zytiga, being a brand-name drug, is generally more expensive. Abiraterone generics are more affordable and widely available, especially through suppliers like Chawla Medicos.
Conclusion
Both abiraterone and Zytiga are effective in managing advanced prostate cancer. The choice between them often comes down to cost and patient preference. Chawla Medicos provides both options at competitive prices, ensuring patients can access the treatment they need.
